Journal of Oncology Pharmacy Practice · 2019 · 20 citations · 23 references
PharmacyClinical PharmacyPharmacy PracticeClinical PharmacologyDrug Utilization ReviewPharmaceutical CareMedication ReviewMedication UseMultiple MyelomaPharmacoepidemiologyPolypharmacy AssessmentPolypharmacy ManagementMultiple Myeloma TherapyMultiple Myeloma TreatmentPolypharmacyPotentially Inappropriate Medication Review
Objective To compare polypharmacy and potentially inappropriate medication use in multiple myeloma patients receiving care under a traditional, physician-managed, or collaborative physician–pharmacist clinic. Design Retrospective chart review. Setting Urban academic cancer center. Data source Computerized electronic record. Patients Forty-four patients in the traditional physician-managed clinic and 57 patients in the collaborative physician-pharmacist clinic. Measurements and main results Patients in the collaborative clinic took fewer medications on average (9 vs. 7, p = 0.045). Although the median number of myeloma-related medications was higher (2 vs. 4, p < 0.0001), the number of non-myeloma-related medications was lower (7 vs. 3, p < 0.0001) in the collaborative clinic. Polypharmacy rates were high in both clinics (93% vs. 84%, p = 0.22). However, the collaborative clinic had a lower rate of polypharmacy of non-myeloma medications (71 vs. 33%, p = 0.0003), including both minor (five to nine medications, 48 vs. 28%, p = 0.06) and major (≥10 medications, 23 vs. 5%, p = 0.02) polypharmacy. Minor polypharmacy of myeloma-related medications was higher in the collaborative clinic (32 vs. 2%; p = 0.0002). Multivariate analysis showed a reduced risk of having a higher number of medications (Relative risk (RR) 0.79, 95% confidence interval 0.67–0.93; p = 0.004), a lower risk of having any polypharmacy of non-myeloma-related medications (RR 0.41, 95% confidence interval 0.25–0.67; p < 0.001) and a lower risk of receiving potentially inappropriate medication (RR 0.62, 95% confidence interval 0.41–0.95; p = 0.029) in the collaborative clinic. Conclusions Multiple myeloma patients have a high rate of polypharmacy but comanagement with a pharmacist reduced the number of all medications, but in particular the number of non-myeloma-related medications.
23
Improved survival in multiple myeloma and the impact of novel therapies
Shaji Kumar, S. Vincent Rajkumar, Angela Dispenzieri et al. · Blood · 2007 · 2.3K citations · Full text
Medicine, Oncology, Pharmacotherapy +14
Global Burden of Multiple Myeloma
Andrew J. Cowan, Christine A. Allen, Aleksandra Barać et al. · JAMA Oncology · 2018 · 634 citations · Full text
Medicine, Health Sciences, Oncology +16
NCCN Task Force Report: Oral Chemotherapy
Saul N. Weingart, Elizabeth Brown, Peter B. Bach et al. · Journal of the National Comprehensive Cancer Network · 2008 · 436 citations · Full text
Medicine, Oncology, Oncology Nursing +13